@MarkusTriska Braun’s work draws its motivation from the chiropractic of #OneSizeFitsAllogist CRM skeleton manipulation — oh, excuse
me, I mean #calibration — to optimize various dose-centered performance characteristics. 4/
@MarkusTriska His mean-field approximation for several such objective functions yields >1000x speedups of calibration procedures that would normally take hours to days. It remains, however, an approximate heuristic, burdened by the conceptual overhead of a fancy #consistency notion. 5/
@MarkusTriska My own approach to these calibration tasks is by contrast elementary: just generate all possible paths in the trial.
I call this ‘complete path enumeration’ (CPE), to distinguish its intent from the aims of the related DTP idea of @ChristinaBYap et al. 6/
@MarkusTriska@ChristinaBYap The price to pay for this conceptual simplicity has been some serious programming. But in one respect this has been an absolute joy, since I’ve been able to do critical portions of it in @rustlang, which I used to implement the CRM integrands. 7/
@MarkusTriska@ChristinaBYap@rustlang@hadleywickham All told, the net speedup is remarkable: I can now CPE (𝑣.𝑡.) a typical-sized CRM trial in mere seconds. The VIOLA trial CPE which
took 17 minutes in an earlier vignette now takes just 1.4 sec on 6 cores. 10/
Interestingly, the trial’s stopping
criteria impose an upper bound on actual enrollment, and thus on the number of possible paths—and on CPE cost as well. 11/
@MarkusTriska@ChristinaBYap@rustlang@hadleywickham The vignette concludes with a Nelder-Mead calibration to optimize the so-called ‘probability of correct selection’ (PCS) of ‘the’ MTD. This takes about 25 minutes, admittedly an order of magnitude greater than the 2 mins Braun attains for his benchmark relating to this task. 12/
@MarkusTriska@ChristinaBYap@rustlang@hadleywickham But as you know by now, I don’t regard such dose-centered calibration activities as useful or even meaningful. Your key takeaway should be that the very same CPE machinery I benchmark in this vignette can just as easily support patient-centered modes of safety analysis. 13/
This latest #DTAT paper @arxiv sets out to reverse-engineer the unstated (∴ unexamined!) pharmacologic intuitions that underlie the #trialsafety claim implicit in the decision to conduct a dose-escalation trial. 2/
Prior elicitation from doctors has never been easy, especially about #pharmacology or the future of the #Daleks: 3/